Correction of cognitive impairment associated with age-dependent cerebral microangiopathy after COVID-19 using the combination drug vinpocetine+piracetam: clinical case report

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cerebral microangiopathy may progress slowly and begin to manifest massive cognitive impairment when a certain brain damage threshold is reached, or more dramatically when inciting events such as infection with the SARS-CoV2 virus occur. Evidence-based therapeutic interventions for post-COVID-19 cognitive impairment have not yet been developed, and clinicians must rely on their own assumptions to help patients. Due to the anti-inflammatory mechanism of action and effectiveness in the treatment of cognitive impairment, as well as good tolerability, the combination drug vinpocetine+piracetam was proposed as a means of correcting cognitive symptoms after COVID-19. The effect of this drug on cognitive function and systemic inflammation, tested by inflammatory markers, was demonstrated in the presented clinical case report.

Full Text

Restricted Access

About the authors

Olga V. Vorobyova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: ovvorobeva@mail.ru
ORCID iD: 0000-0001-5070-926X

Dr. Sci. (Med.), Professor at the Department of Nervous Diseases, Institute of Professional Education

Russian Federation, Moscow

References

  1. Das A.S., Regenhardt R.W., Blacker D., et al. Asymptomatic cerebral small vessel disease: insights from population-based studies. J Stroke. 2019;21:121. doi: 10.5853/jos.2018.03608.
  2. Raveendran A., Jayadevan R., Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr Clin Res Rev. 2021;15(3):869–75. doi: 10.1016/j.dsx.2021.04.007.
  3. Di Toro A., Bozzani A., Tavazzi G., et al. Long COVID: long-term effects? Eur Heart J Suppl. 2021;23(Suppl. E):E1–5. doi: 10.1093/eurheartj/suab080.
  4. Guo P., Benito Ballesteros A., Yeung S.P., et al. COVCOG 2: cognitive and memory deficits in long COVID: a second publication from the COVID and cognition study. Front Aging Neurosci. 2022:14. doi: 10.3389/fnagi.2022.804937.
  5. Becker J.H., Lin J.J., Doernberg M., et al. Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open. 2021;4(10). doi: 10.1001/jamanetworkopen.2021.30645.
  6. Otifi H.M., Adiga B.K. Endothelial dysfunction in covid-19 infection. Am J Med Sci. 2022;363(4):281–87. doi: 10.1016/j.amjms.2021.12.010.
  7. Seitz A., Ong P. Endothelial dysfunction in COVID-19: A Potential predictor of long-COVID. Int J Cardiol. 2022;349:155–56. doi: 10.1016/j.ijcard.2021.11.051.
  8. Ambrosino P., Calcaterra I., Molino A., et al. Persistent endothelial dysfunction in post-acute COVID-19 syndrome: a case-control study. Biomed. 2021;9(8). doi: 10.3390/biomedicines9080957.
  9. Charfeddine S., Ibn Hadj Amor H., Jdidi J., et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:1702. doi: 10.3389/fcvm.2021.745758.
  10. Tong M., Jiang Y., Xia D., et al. Elevated expression of serum endothelial cell adhesion molecules in COVID-19 patients. J Infect Dis. 2020;222:894–98. doi: 10.1093/infdis/jiaa349.
  11. Balestreri R., Fontana L., Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987;35:425–30
  12. Szatmari S.Z., Whitehouse P.J. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;1:CD003119.
  13. Deshmukh R., Sharma V., Mehan S., et al. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. Eur J Pharmacol. 2009;620: 49–56 .
  14. Hindmarch I., Fuchs H.H., Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 1991;6:31–43.
  15. Medina A.E. Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A. 2010;107(22):9921–22. doi: 10.1073/pnas.1005138107.
  16. Wang H., Zhang K., Zhao L., et al. Anti-inflammatory effects of vinpocetine on the functional expression of nuclear factor-kappa B and tumor necrosis factoralpha in a rat model of cerebral ischemia-reperfusion injury. Neurosci Lett. 2014;566:247–51.
  17. Воробьева О.В., Тамарова Е.С. Эффективность винпотропила в терапии ранних проявлений цереброваскулярной патологии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;9:39–44. [Vorobyova O.V., Tamarova E.S. The effectiveness of vinpotropil in the treatment of early manifestations of cerebrovascular pathology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;9:39–44. (In Russ.)].
  18. Захаров В.В., Локшина А., Стаховская Л.В. и др. Опыт применения комбинированного препарата винпотропил на ранних стадиях дисциркуляторной энцефалопатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007;9:45–51. [Zakharov V.V., Lokshina A., Stakhov-skaya L.V.,et al. Experience with the use of the combined drug vinpotropil in the early stages of dyscirculatory encephalopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;9:45–51. (In Russ.)].
  19. Камчатнов П.Р., Абусуева Б.А., Чугунов А.В. Применение Винпотропила при ишемических поражениях головного мозга. Поликлиника. 2015;5:13–6. [Kamchatnov P.R., Abusueva B.A., Chugunov A.V. Use of Vinpotropil for ischemic brain lesions. Poliklinika. 2015;5:13–6. (In Russ.)].
  20. Julayanont P., Brousseau M., Chertkow H., et al. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer’s disease. J Am Geriatr Soc. 2014;62(4):679–84. https://doi.org/10.1111/jgs.12742
  21. Garcia-Sanchez C., Calabria M., Grunden N., et al. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain Behav. 2022;12:e2508. doi: 10.1002/brb3.250.
  22. Delgado-Alonso C., Valles-Salgado M., Delgado-Alvarez A., et al. Cognitive dysfunction associated with COVID-19: a comprehensive neuropsychological study. J Psychiatr Res. 2022;150:40–6. doi.org/10.1016/j.jpsychires.2022.03.033

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies